KURA vs. EXEL

Last updated Apr 1, 2026

Compare and contrast key facts about Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL).

Performance

KURA vs. EXEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL). The values are adjusted to include any dividend payments, if applicable.

KURA vs. EXEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
KURA Kura Oncology, Inc.	-21.75%	19.29%	-39.43%	15.87%	-11.36%	-57.13%	137.53%	-2.07%	-8.24%	159.32%
EXEL Exelixis, Inc.	0.48%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%

Fundamentals

Market Cap KURA : $715.85M EXEL : $12.41B
EPS KURA : -$3.18 EXEL : $2.76
PS Ratio KURA : 10.57 EXEL : 5.38
PB Ratio KURA : 4.11 EXEL : 5.74
Total Revenue (TTM) KURA : $67.48M EXEL : $2.32B
Gross Profit (TTM) KURA : $63.81M EXEL : $2.24B
EBITDA (TTM) KURA : -$290.02M EXEL : $934.65M

Returns By Period

In the year-to-date period, KURA achieves a -21.75% return, which is significantly lower than EXEL's 0.48% return. Over the past 10 years, KURA has underperformed EXEL with an annualized return of 8.64%, while EXEL has yielded a comparatively higher 26.95% annualized return.

KURA

• 1D: 5.17%
• 1M: -6.34%
• YTD: -21.75%
• 6M: -11.63%
• 1Y: 27.43%
• 3Y*: -12.73%
• 5Y*: -22.63%
• 10Y*: 8.64%

EXEL

• 1D: 2.68%
• 1M: 7.34%
• YTD: 0.48%
• 6M: 6.89%
• 1Y: 21.02%
• 3Y*: 31.40%
• 5Y*: 13.76%
• 10Y*: 26.95%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KURA vs. EXEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KURA

KURA Risk / Return Rank: 52
KURA Sharpe Ratio Rank: 55
KURA Sortino Ratio Rank: 55
KURA Omega Ratio Rank: 51
KURA Calmar Ratio Rank: 50
KURA Martin Ratio Rank: 51

EXEL

EXEL Risk / Return Rank: 57
EXEL Sharpe Ratio Rank: 57
EXEL Sortino Ratio Rank: 53
EXEL Omega Ratio Rank: 56
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KURA vs. EXEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KURA	EXEL	Difference
Sharpe ratio Return per unit of total volatility	0.38	0.48	-0.10
Sortino ratio Return per unit of downside risk	0.99	0.97	+0.02
Omega ratio Gain probability vs. loss probability	1.11	1.14	-0.03
Calmar ratio Return relative to maximum drawdown	0.39	0.76	-0.37
Martin ratio Return relative to average drawdown	0.92	1.78	-0.85
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KURA vs. EXEL - Sharpe Ratio Comparison

The current KURA Sharpe Ratio is 0.38, which is comparable to the EXEL Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of KURA and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KURA	EXEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.38	0.48	-0.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.37	0.38	-0.75
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.12	0.60	-0.48
Sharpe Ratio (All Time) Calculated using the full available price history	0.00	0.07	-0.06

Correlation

The correlation between KURA and EXEL is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KURA vs. EXEL - Dividend Comparison

Neither KURA nor EXEL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

KURA vs. EXEL - Drawdown Comparison

The maximum KURA drawdown since its inception was -86.69%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for KURA and EXEL.

Drawdown Indicators

	KURA	EXEL	Difference
Max Drawdown Largest peak-to-trough decline	-86.69%	-97.38%	+10.69%
Max Drawdown (1Y) Largest decline over 1 year	-39.04%	-25.34%	-13.70%
Max Drawdown (5Y) Largest decline over 5 years	-81.46%	-41.47%	-39.99%
Max Drawdown (10Y) Largest decline over 10 years	-86.69%	-57.20%	-29.49%
Current Drawdown Current decline from peak	-80.47%	-10.58%	-69.89%
Average Drawdown Average peak-to-trough decline	-46.69%	-71.54%	+24.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.61%	10.86%	+5.75%

Volatility

KURA vs. EXEL - Volatility Comparison

Kura Oncology, Inc. (KURA) has a higher volatility of 15.28% compared to Exelixis, Inc. (EXEL) at 7.20%. This indicates that KURA's price experiences larger fluctuations and is considered to be riskier than EXEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KURA	EXEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.28%	7.20%	+8.08%
Volatility (6M) Calculated over the trailing 6-month period	41.69%	26.65%	+15.04%
Volatility (1Y) Calculated over the trailing 1-year period	61.02%	43.83%	+17.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.30%	36.85%	+24.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.13%	44.88%	+25.25%

Financials